Charles River Laboratories International (CRL) Expected to Announce Quarterly Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Charles River Laboratories International to post earnings of $2.97 per share and revenue of $960.36 million for the quarter. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same quarter last year, the firm earned $3.12 EPS. Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. On average, analysts expect Charles River Laboratories International to post $11.38 EPS for the current fiscal year and $12.58 EPS for the next fiscal year.

Charles River Laboratories International Stock Down 6.0%

Shares of Charles River Laboratories International stock opened at $337.80 on Tuesday. The firm has a market cap of $16.13 billion, a PE ratio of -69.65, a P/E/G ratio of 3.50 and a beta of 1.40. The business’s 50 day simple moving average is $302.94 and its 200 day simple moving average is $222.94. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International has a 52-week low of $146.20 and a 52-week high of $379.63.

Analyst Ratings Changes

CRL has been the subject of several research reports. Argus set a $330.00 price target on shares of Charles River Laboratories International in a research note on Thursday, September 17th. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $180.00 to $310.00 in a report on Thursday, August 6th. Zacks Research raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Finally, UBS Group began coverage on shares of Charles River Laboratories International in a report on Wednesday, September 30th. They set a “buy” rating and a $357.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $302.33.

Insiders Place Their Bets

In related news, CEO Birgit Girshick sold 6,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the sale, the chief executive officer owned 36,013 shares in the company, valued at approximately $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of the company’s stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the sale, the executive vice president owned 4,807 shares in the company, valued at $1,655,578.87. The trade was a 30.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 118,169 shares of company stock valued at $35,191,216 in the last quarter. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.